Selective Delivery of Low-Affinity IL-2 to PD-1⁺ T Cells Rejuvenates Antitumor Immunity with Reduced Toxicity

Investigators observed that anti–PD-1 therapy depends on IL-2 signaling, which raised the possibility that a lack of IL-2 limited anti–PD-1–induced effector T cell expansion.